Welcome!
Boehringer Ingelheim
Healthcare
Boehringer Ingelheim to acquire assets, IP from Singapore biotech firm in deal worth more than US$1 bil
The deal is the largest for any biotech company in Singapore, and among the biggest globally for preclinical stage programmes.
January 09, 2020